Suppr超能文献

尼日利亚乔斯住院患者中的抗结核药物与肝毒性

Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria.

作者信息

Isa Samson E, Ebonyi Augustine O, Shehu Nathan Y, Idoko Patrick, Anejo-Okopi Joseph A, Simji Gomerep, Odesanya Rachael U, Abah Isaac O, Jimoh Hafsat O

机构信息

Department of Medicine, University of Jos/Jos University Teaching Hospital, Jos, Nigeria; AIDS Prevention Initiative in Nigeria (APIN), Jos University Teaching Hospital, Jos, Nigeria.

AIDS Prevention Initiative in Nigeria (APIN), Jos University Teaching Hospital, Jos, Nigeria; Department of Pediatrics, University of Jos/Jos University Teaching Hospital, Jos, Nigeria.

出版信息

Int J Mycobacteriol. 2016 Mar;5(1):21-6. doi: 10.1016/j.ijmyco.2015.10.001. Epub 2015 Oct 30.

Abstract

BACKGROUND

Tuberculosis (TB) could be fatal if left untreated, however, adverse effects of anti-TB medications (anti-TBs) themselves may limit treatment. We determined the incidence and clinical characteristics of hepatotoxicity in hospitalized patients receiving first-line anti-TB treatment.

METHODS

A retrospective cohort study of patients aged ⩾18years seen at the medical wards of the Jos University Teaching Hospital from January 2013 to June 2013 was carried out. Data were retrieved for 110 patients who were prescribed anti-TBs. Their demographic and clinical characteristics were described, and the incidence of symptomatic hepatotoxicity determined. The incidence of hepatotoxicity by strict American Thoracic Society criteria (symptomatic hepatotoxicity plus alanine transaminase in IU/L levels >3×upper limit of normal) was also determined.

RESULTS

Twenty patients developed symptomatic hepatotoxicity, giving an incidence of 18.2%. Furthermore, 18 (16.4%) patients had hepatotoxicity according to the American Thoracic Society criteria. Those with symptomatic hepatotoxicity unexpectedly had lower baseline alanine transaminase interquartile range (IQR) (35 [16-63] vs. 67 [4-226]; p=.04) and bilirubin (μmol/L): total IQR (15.3 [10.2-74.8] vs. 20.4 [20.4-20.4]; p=.01) and conjugated IQR (7.6 [5.1-34.8] vs. 10.2 [10.2-10.2]; p=.004). However, there were no significant differences in age, sex, body mass index, and duration of anti-TB treatment, human immunodeficiency virus infection status, antiretroviral therapy status, alcohol consumption, and the presence of hepatitis B surface antigen or hepatitis C virus antibody.

CONCLUSION

Hepatotoxicity due to first-line anti-TBs, whether based on clinical features alone or backed by liver chemistry, is common among hospitalized patients in our environment. Studies to determine the predictors of hepatotoxicity to guide clinical interventions aimed at the prevention or timely identification of cases are needed.

摘要

背景

肺结核(TB)若不治疗可能会致命,然而,抗结核药物(抗TBs)本身的不良反应可能会限制治疗。我们确定了接受一线抗结核治疗的住院患者肝毒性的发生率及临床特征。

方法

对2013年1月至2013年6月在乔斯大学教学医院内科病房就诊的年龄≥18岁的患者进行了一项回顾性队列研究。检索了110例开具抗TBs药物患者的数据。描述了他们的人口统计学和临床特征,并确定了有症状肝毒性的发生率。还根据美国胸科学会的严格标准(有症状肝毒性加国际单位/升水平的丙氨酸转氨酶>正常上限的3倍)确定了肝毒性的发生率。

结果

20例患者出现有症状肝毒性,发生率为18.2%。此外,根据美国胸科学会标准,18例(16.4%)患者有肝毒性。有症状肝毒性的患者基线丙氨酸转氨酶四分位数间距(IQR)意外较低(35[16 - 63]对67[4 - 226];p = 0.04)以及胆红素(微摩尔/升):总IQR(15.3[10.2 - 74.8]对20.4[20.4 - 20.4];p = 0.01)和结合胆红素IQR(7.6[5.1 - 34.8]对10.2[10.2 - 10.2];p = 0.004)。然而,在年龄、性别、体重指数、抗结核治疗持续时间、人类免疫缺陷病毒感染状况、抗逆转录病毒治疗状况、饮酒情况以及乙肝表面抗原或丙肝病毒抗体的存在方面没有显著差异。

结论

在我们所处环境的住院患者中,一线抗TBs药物所致肝毒性很常见,无论仅基于临床特征还是有肝脏化学指标支持。需要开展研究以确定肝毒性的预测因素,从而指导旨在预防或及时识别病例的临床干预措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验